Deubiquitylation and stabilization of PTEN by USP13

Jinsong Zhang1, Peijing Zhang1,6, Yongkun Wei2,6, Hai-long Piao1, Wenqi Wang1, Subbareddy Maddika3, Min Wang1, Dahu Chen1, Yutong Sun2, Mien-Chie Hung2,4,5, Junjie Chen1,4 and Li Ma1,4,7

The tumour suppressor PTEN is frequently lost in human cancers. In addition to gene mutations and deletions, recent studies have revealed the importance of post-translational modifications, such as ubiquitylation, in the regulation of PTEN stability, activity and localization. However, the deubiquitylase that regulates PTEN polyubiquitylation and protein stability remains unknown. Here we screened a total of 30 deubiquitylating enzymes (DUBs) and identified five DUBs that physically associate with PTEN. One of them, USP13, stabilizes the PTEN protein through direct binding and deubiquitylation of PTEN. Loss of USP13 in breast cancer cells promotes AKT phosphorylation, cell proliferation, anchorage-independent growth, glycolysis and tumour growth through downregulation of PTEN. Conversely, overexpression of USP13 suppresses tumorigenesis and glycolysis in PTEN-positive but not PTEN-null breast cancer cells. Importantly, USP13 protein is downregulated in human breast tumours and correlates with PTEN protein levels. These findings identify USP13 as a tumour-suppressing protein that functions through deubiquitylation and stabilization of PTEN.

The lipid phosphatase PTEN (phosphatase and tensin homologue deleted on chromosome 10) catalyses the conversion of phosphatidylinositol-3,4,5-trisphosphate to phosphatidylinositol-4,5-bisphosphate1-2. By antagonizing PI(3)K–AKT signalling, PTEN plays crucial roles in many cellular processes3-5. This protein is encoded by a tumour suppressor gene located at 10q23 (ref. 6), which is one of the most frequently mutated genes in human cancer7-8. Germline PTEN mutations occur in several inherited syndromes (such as Cowden syndrome) characterized by hamartomatous growth and predispensation to breast, thyroid and endometrial cancers, and somatic mutations of PTEN are observed in a wide cancer spectrum, including breast, prostate, kidney and brain tumours2-9.

Despite frequent genetic alterations of PTEN in human tumours, only 25% of cancer patients show a correlation between loss of PTEN protein and loss of its messenger RNA9, which underscores the importance of PTEN regulation at post-transcriptional and post-translational levels. Indeed, mono- or polyubiquitylation, phosphorylation, sumoylation, acetylation and regulation by non-coding RNAs can control PTEN expression, activity or localization3,10,11,12. Whereas recent studies have revealed the role of ubiquitylation in modulating the PTEN protein3,10,11,12, the regulation of PTEN deubiquitylation remains poorly understood. Several ubiquitin ligases of PTEN, including NEDD4-1 (refs 13,14), WWP2 (ref. 15), XIAP (ref. 16) and CHIP (ref. 17), have been found to target PTEN for proteasomal degradation. On the other hand, reversal of the mono-ubiquitylation of PTEN by USP7 (also known as HAUSP) regulates PTEN subcellular localization without affecting its protein level18. However, the deubiquitylase that regulates PTEN polyubiquitylation and protein stability has not been reported.

In this study, we identified USP13 as the first deubiquitylase that reverses PTEN polyubiquitylation and stabilizes PTEN protein, and found that USP13 suppresses tumorigenesis and glycolysis through PTEN. In human breast cancer, loss of USP13 is highly associated with loss of PTEN.

RESULTS

USP13 regulates PTEN protein level and AKT signalling

DUBs are a group of proteases that regulate ubiquitin-dependent pathways by cleaving ubiquitin–protein bonds19. To identify PTEN-interacting deubiquitylases, we screened a panel of DUBs, in which a total of 30 deubiquitylase open reading frames (ORFs) were fused with a triple-epitope tag, SFB (S-protein, FLAG tag and streptavidin-binding peptide), and then co-transfected with MYC-tagged PTEN into HEK293T cells. Immunoblotting assays showed that MYC-PTEN could be detected on S-protein beads conjugated with five DUBs, USP7, USP8, USP10, USP13 or USP39 (Fig. 1a). Moreover, MYC–PTEN transfected into HeLa cells could also be pulled down by each of these five SFB-tagged DUBs (Fig. 1b), further corroborating a physical association.

1Department of Experimental Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. 2Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA. 3Laboratory of Cell Death and Cell Survival, Centre for DNA Fingerprinting and Diagnostics (CDFD), Nampally, Hyderabad 500001, India. 4Cancer Biology Program, Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, Texas 77030, USA. 5Center for Molecular Medicine and Graduate Institute of Cancer Biology, China Medical University, Taichung 402, Taiwan. 6These authors contributed equally to this work.

7Correspondence should be addressed to L.M. (e-mail: lma4@mdanderson.org)

Received 27 May 2013; accepted 8 October 2013; published online 24 November 2013; DOI: 10.1038/ncb2874
**Figure 1** USP13 is a PTEN-interacting deubiquitylase that regulates PTEN and AKT signalling. (a) Five of 30 DUBs physically associate with PTEN. SFB-tagged DUBs were co-transfected with MYC–PTEN into HEK293T cells, followed by pulldown with S-protein beads and immunoblotting with antibodies against FLAG and MYC. (b) Five SFB-tagged DUBs were co-transfected with MYC–PTEN into HeLa cells, followed by pulldown with S-protein beads and immunoblotting with antibodies against MYC and FLAG. (c) Immunoblotting of USP13, PTEN, p-AKT, AKT, p-FOXO1, p-FOXO3, FOXO1, cyclin A2, PLK1 and β-actin in BT549 and MDA-MB-231 cells transduced with wild-type USP13 or the USP13<sup>C345A</sup> mutant. (d) Immunoblotting of USP13, PTEN, p-AKT, AKT, p-FOXO1, p-FOXO3, FOXO1, cyclin A2, PLK1 and HSP90 in USP13 shRNA-transduced SUM159 cells with or without ectopic expression of PTEN. (e–g) Immunoblotting of USP13, PTEN, p-AKT, AKT, p-FOXO1, p-FOXO3, FOXO1 and HSP90 (or GAPDH) in USP13 shRNA-transduced MCF10A (e), MCF7 (f), HCT116<sup>PTEN<sup>+/+</sup></sup> and HCT116<sup>PTEN<sup>−/−</sup></sup> (g) cells. Uncropped images of blots are shown in Supplementary Fig. 6.

To examine the effects of these five PTEN-associated DUBs on PTEN expression and the growth of tumour cells, we stably expressed them individually in the MCF7 human breast cancer cell line. Although each of these five DUBs could interact with endogenous PTEN (Supplementary Fig. 1a), only one of them, USP13, significantly increased endogenous PTEN protein expression (Supplementary Fig. 1a). Compared with the control MCF7 cells, cells overexpressing USP7, USP10 or USP13 exhibited a pronounced reduction in both proliferation (Supplementary Fig. 1b) and anchorage-independent growth (Supplementary Fig. 1c,d). Therefore, USP13 stood out as the top candidate for a possible PTEN deubiquitylase and a putative tumour suppressor.

As an alternative approach to identify PTEN-associated DUBs, we isolated PTEN-containing protein complexes using SFB-tagged
USP13 regulates the PTEN protein level but not its subcellular localization. (a) Immunofluorescent staining of USP13 (red) and PTEN (green) in MDA-MB-231 cells transduced with wild-type USP13 or the USP13 C345A mutant. The right panels are the overlay of USP13, PTEN and nuclear 4',6-diamidino-2-phenylindole (DAPI; blue) staining of the same field. The GFP and RFP sequences in the pLOC vector were mutated to silence GFP and RFP expression from this vector. Scale bar, 10 μm. (b) Immunofluorescent staining of USP13 (red) and PTEN (green) in SUM159 cells infected with USP13 shRNA or the pGIPZ vector with a scrambled sequence. The right panels are the overlay of USP13, PTEN and nuclear DAPI staining of the same field. The GFP sequence in the pGIPZ vector was mutated to silence GFP expression from this vector. Scale bar, 10 μm. (c) Immunoblotting of MYC-PTEN, FLAG-USPs, HSP90 (cytoplasmic marker) and lamin B (nuclear marker) in cytoplasmic (C) and nuclear (N) fractions of PC3 cells co-transfected with MYC-PTEN and FLAG-tagged USP13 or USP7. (d) Immunoblotting of MYC-PTEN, FLAG-USPs, HSP90 and lamin B (nuclear marker) in cytoplasmic (C) and nuclear (N) fractions of PC3 cells co-transfected with MYC-PTEN and FLAG-tagged USP13 or USP7. Uncropped images of blots are shown in Supplementary Fig. 6.

PTEN. Tandem affinity purification using streptavidin–Sepharose beads and S-protein agarose beads followed by mass spectrometric analysis identified six DUBs, USP10, USP13, USP7, USP8, USP39 and USP4, as PTEN interactors (Supplementary Table 1). Conversely, purification of SFB-tagged USP13 complexes identified PTEN as a USP13-interacting protein (Supplementary Table 2).

Next, we expressed USP13 in other human breast cancer cells. This overexpression upregulated PTEN protein and downregulated AKT, FOXO1 and FOXO3 phosphorylation in the MDA-MB-231 cell line (Fig. 1c), which expresses moderate but detectable levels of endogenous PTEN (Supplementary Fig. 2a), and knockdown of PTEN in USP13-overexpressing MDA-MB-231 cells rescued the phosphorylation of both AKT, FOXO1 and FOXO3 (Supplementary Fig. 2b). In contrast, expression of USP13 did not reduce phospho-AKT and phospho-FOXO levels in BT549 cells (Fig. 1c), which showed no PTEN protein expression (Supplementary Fig. 2a) owing to a frameshift mutation20,21. Overexpression of a catalytically inactive mutant of USP13, C345A (ref. 22), had no effect on PTEN protein levels and the phosphorylation of AKT, FOXO1 and FOXO3 in these two cell lines (Fig. 1c).

To further validate regulation of the PTEN protein by USP13, we performed loss-of-function analysis in multiple cell lines that express abundant USP13 and PTEN protein levels. Two independent USP13 short hairpin RNAs (shRNAs) both decreased PTEN protein expression by 80% and increased phospho-AKT and phospho-FOXO1 and -FOXO3 levels by three- to fivefold in SUM159 breast cancer cells, and restoration of PTEN or expression of an RNAi-resistant ‘silence mutant’ (that is, no amino acid change) of USP13 (USP13-RE) in USP13-depleted SUM159 cells completely reversed the effect of USP13 shRNA on upregulating the phosphorylation of AKT and FOXO (Fig. 1d and Supplementary Fig. 2c,d). Similarly, depletion of USP13 downregulated PTEN protein and upregulated AKT, FOXO1 and FOXO3 phosphorylation in MCF10A (Fig. 1e) and MCF7 (Fig. 1f) mammary epithelial cells and in HCT116 colon cancer cells (Fig. 1g), but not in the isogenic PTEN-null HCT116 cells (Fig. 1g). In addition, USP13 shRNA potentiated insulin-induced AKT phosphorylation in SUM159 cells, which could be reversed by re-expression of PTEN (Supplementary Fig. 2e). We conclude from these data that USP13 inhibits AKT signalling through positive regulation of PTEN protein. It should be noted that neither knockdown nor overexpression of USP13 affected PTEN mRNA levels (Supplementary Fig. 3a,b). Thus, USP13 does not regulate PTEN expression at the transcriptional level.

In contrast to the knockdown effect of USP13, silencing of the other four PTEN-interacting DUBs, USP7, USP8, USP10 or USP39, did not affect PTEN protein levels (Supplementary Fig. 4a–d). USP7 (HAUSP), the only known PTEN deubiquitylase reported so far,
Figure 3 USP13 directly interacts with and deubiquitylates PTEN. (a) HEK293T cells were transfected with MYC–PTEN alone or in combination with FLAG-tagged USP13 or the USP13<sup>C345A</sup> mutant, immunoprecipitated with FLAG beads and immunoblotted with antibodies against MYC and FLAG. (b) Endogenous USP13 was immunoprecipitated from SUM159 cells and immunoblotted with antibodies against USP13 and PTEN. (c) Top: GST–GFP or GST–USP13 was retained on glutathione-Sepharose beads, incubated with extracts of FLAG–PTEN-transfected HEK293T cells and then immunoblotted with the antibody against FLAG. Bottom: recombinant GST–GFP and GST–USP13 were purified from bacteria and analysed by SDS–PAGE and Coomassie blue staining. (d) Schematic representation of FLAG-tagged full-length PTEN (FL) and its various deletion mutants (M1–M7). (e) HEK293T cells were co-transfected with MYC–USP13 and FLAG-tagged full-length PTEN or its deletion mutants, immunoprecipitated with FLAG beads and immunoblotted with antibodies against MYC and FLAG. (f) HEK293T cells were co-transfected with MYC–PTEN, USP13 shRNA and HA–ubiquitin (Ub), immunoprecipitated with MYC beads and immunoblotted with antibodies against HA and MYC. Cells were treated with MG132 (10 μM) for 6 h before collection. (g) HEK293T cells were co-transfected with MYC–PTEN, HA–ubiquitin (Ub) and FLAG-tagged USP13 or the USP13<sup>C345A</sup> mutant, immunoprecipitated with MYC beads and immunoblotted with antibodies against HA and MYC. Cells were treated with MG132 (10 μM) for 6 h before collection. (h) Top: unubiquitylated or ubiquitylated SFB–PTEN was incubated with GST-tagged USP13 or the USP13<sup>C345A</sup> mutant purified from bacteria with glutathione–Sepharose beads. After reaction, SFB–PTEN was immunoprecipitated with FLAG beads and immunoblotted with antibodies against HA and FLAG. Bottom (input for the in vitro assay): SFB–PTEN was purified with streptavidin–Sepharose beads and immunoblotted with the antibody against FLAG. Recombinant GST–USP13 was purified from bacteria and analysed by SDS–PAGE and Coomassie blue staining. (i) Top: unubiquitylated or ubiquitylated SFB–PTEN was incubated with SFB-tagged USP13 or the USP13<sup>C345A</sup> mutant purified from HEK293T cells with streptavidin–Sepharose beads. After reaction, PTEN was immunoprecipitated with the antibody against PTEN and immunoblotted with the antibody against PTEN. Bottom (input for the in vitro assay): SFB–USP13 and SFB–PTEN were purified with streptavidin–Sepharose beads and immunoblotted with antibodies against USP13 and FLAG, respectively. Uncropped images of blots are shown in Supplementary Fig. 6.
We sought to determine whether USP13 directly interacts with PTEN without affecting total PTEN protein levels (Fig. 2c,d), consistent with (C345A). Indeed, silencing USP13 expression by two independent shRNAs demonstrated that the phosphatase domain of PTEN is essential for its deletion mutants of PTEN on PTEN, we co-expressed MYC-tagged USP13 along with a series of a carboxy-terminal PDZ motif consists of an amino-terminal phosphatase domain, a C2 domain and functions as a PTEN deubiquitylase. Consistent with CDH1 complex, which has been shown to.

In the present study, immunofluorescent staining (Fig. 2a,b) and fractionation assays (Fig. 2c,d) demonstrated that manipulating USP13 levels altered PTEN protein expression but not its localization; moreover, either overexpression or knockdown of USP13 had no effect on the levels of cyclin A2 and PLK1 (Fig. 1c,d), the key substrates of the APC–CDH1 complex, which has been shown to be regulated by nuclear PTEN in a phosphatase-independent manner. In contrast, USP7 reduced nuclear localization of PTEN in PC3 cells without affecting total PTEN protein levels (Fig. 2c,d), consistent with previously reported findings.

**USP13 deubiquitylates and stabilizes PTEN**

We sought to determine whether USP13 directly interacts with PTEN and functions as a bona fide PTEN deubiquitylase. Consistent with the interaction observed in the initial screen, co-immunoprecipitation assays confirmed that ectopically expressed MYC-tagged PTEN could be detected in FLAG-tagged wild-type or the C345A mutant of USP13 immunoprecipitates (Fig. 3a), and that endogenous PTEN was present in endogenous USP13 immunoprecipitates (Fig. 3b). Moreover, purified GST–USP13, but not the GST–GFP control, was able to bind to FLAG-tagged PTEN under cell-free conditions (Fig. 3c), which demonstrated a direct interaction between USP13 and PTEN. PTEN consists of an amino-terminal phosphatase domain, a C2 domain and a carboxy-terminal PDZ motif. To map the USP13-binding region on PTEN, we co-expressed MYC-tagged USP13 along with a series of deletion mutants of PTEN (Fig. 3d). Co-immunoprecipitation assays demonstrated that the phosphatase domain of PTEN is essential for its physical interaction with USP13 (Fig. 3e).

We reasoned that USP13 regulates PTEN through deubiquitylation. Indeed, silencing USP13 expression by two independent shRNAs increased PTEN polyubiquitylation by approximately threefold (Fig. 3f). On the other hand, ectopic expression of wild-type USP13, but not the C345A mutant, which is still capable of interacting with PTEN (Fig. 3a), reduced the polyubiquitylation of PTEN by 65% (Fig. 3g), suggesting that the enzymatic activity of USP13 is indispensable for USP13-dependent deubiquitylation of PTEN. To determine whether PTEN is a direct substrate of USP13, we purified USP13 and ubiquitylated PTEN and then incubated them in a cell-free system. Wild-type USP13 purified from either bacteria or HEK293T cells, but not its catalytically inactive mutant C345A, decreased PTEN polyubiquitylation by 64–70% in vitro (Fig. 3h,i). Therefore, USP13 can directly deubiquitylate PTEN.

To determine whether USP13 regulates the stability of the PTEN protein, we examined ectopically expressed or endogenous PTEN protein levels in the presence of cycloheximide (CHX), an inhibitor of protein translation. Notably, overexpression of USP13, but not the enzyme-dead mutant, led to a prominent increase in the stability of endogenous or overexpressed PTEN protein, whereas the stability of HSP90 or co-transfected GFP control was not affected (Fig. 4a,b).

Conversely, knockdown of USP13 resulted in destabilization of the PTEN protein (Fig. 4c,d). Collectively, these results suggest that USP13 is a PTEN deubiquitylase that stabilizes PTEN.

**Loss of USP13 promotes tumorigenesis through downregulation of PTEN**

We investigated whether USP13 functions as a tumour-suppressing protein by regulating PTEN. Two independent USP13 shRNAs (Fig. 1d) both markedly increased the proliferation (Fig. 5a) and anchorage-independent growth (Fig. 5b,c) of SUM159 breast cancer cells, and restoration of PTEN (Fig. 1d) or expression of an RNAi-resistant USP13 mutant (Supplementary Fig. 2c,d) completely reversed the increased PTEN polyubiquitylation by approximately threefold (Fig. 3f). On the other hand, ectopic expression of wild-type USP13, but not the C345A mutant, which is still capable of interacting with PTEN (Fig. 3a), reduced the polyubiquitylation of PTEN by 65% (Fig. 3g), suggesting that the enzymatic activity of USP13 is indispensable for USP13-dependent deubiquitylation of PTEN. To determine whether PTEN is a direct substrate of USP13, we purified USP13 and ubiquitylated PTEN and then incubated them in a cell-free system. Wild-type USP13 purified from either bacteria or HEK293T cells, but not its catalytically inactive mutant C345A, decreased PTEN polyubiquitylation by 64–70% in vitro (Fig. 3h,i). Therefore, USP13 can directly deubiquitylate PTEN.

To determine whether USP13 regulates the stability of the PTEN protein, we examined ectopically expressed or endogenous PTEN protein levels in the presence of cycloheximide (CHX), an inhibitor of protein translation. Notably, overexpression of USP13, but not the enzyme-dead mutant, led to a prominent increase in the stability of endogenous or overexpressed PTEN protein, whereas the stability of HSP90 or co-transfected GFP control was not affected (Fig. 4a,b). Conversely, knockdown of USP13 resulted in destabilization of the PTEN protein (Fig. 4c,d). Collectively, these results suggest that USP13 is a PTEN deubiquitylase that stabilizes PTEN.

**Loss of USP13 promotes tumorigenesis through downregulation of PTEN**

We investigated whether USP13 functions as a tumour-suppressing protein by regulating PTEN. Two independent USP13 shRNAs (Fig. 1d) both markedly increased the proliferation (Fig. 5a) and anchorage-independent growth (Fig. 5b,c) of SUM159 breast cancer cells, and restoration of PTEN (Fig. 1d) or expression of an RNAi-resistant USP13 mutant (Supplementary Fig. 2c,d) completely reversed the
Figure 5 Loss of USP13 promotes tumour growth and glycolysis through downregulation of PTEN. (a) Growth curves of USP13 shRNA-transduced SUM159 cells with or without ectopic expression of PTEN. (b,c) Images (b) and quantification (c) of anchorage-independent growth of USP13 shRNA-transduced SUM159 cells with or without ectopic expression of PTEN. (d) Growth curves of USP13 shRNA-transduced SUM159 cells with or without ectopic expression of an RNAi-resistant mutant of USP13 (USP13-RE). (e) Growth curves of USP13 shRNA-transduced HCT116 cells with or without ectopic expression of PTEN. (f) Immunoblots of USP13, p-AKT, AKT and HSP90 in USP13 shRNA-transduced SUM159 cells cultured in the presence or absence of the AKT inhibitor MK-2206 (1 μM). (g,h) Lactate secretion (g) and 2-deoxy-D-[3H]glucose (H3-DG) uptake (h) by USP13 shRNA-transduced SUM159 cells with or without ectopic expression of PTEN. (i) Tumour growth by 5 × 10^6 subcutaneously injected USP13 shRNA-transduced SUM159 cells with or without ectopic expression of PTEN. (j,k) Tumour weight (j) and tumour images (k) of mice with subcutaneous injection of 5 × 10^6 USP13 shRNA-transduced SUM159 cells with or without ectopic expression of PTEN, at day 65 after implantation. Data in a and c–j are mean ± s.e.m. n = 5 mice per group in (i,j). Statistical significance was determined by a two-tailed, unpaired Student’s t-test. (l) Immunoblotting of USP13, PTEN, p-AKT, AKT and β-actin in tumour lysates from k. Data in a and c–h are the mean of 3 wells per group and error bars indicate s.e.m. The experiments were repeated three times. The source data for a and c–h can be found in Supplementary Table 3. Uncropped images of blots are shown in Supplementary Fig. 6.

The effect of USP13 shRNA (Fig. 5a–d). Moreover, knockdown of USP13 promoted the proliferation of HCT116 colon cancer cells but not the isogenic PTEN-null HCT116 cells (Fig. 5e).

The effect of USP13 shRNA on cell proliferation is AKT-dependent, as treatment with the AKT inhibitor MK-2206 abolished this effect (Fig. 5f). Furthermore, because USP13 regulates AKT phosphorylation through PTEN (Fig. 1c–g), and because AKT plays a critical role in regulating the Warburg effect whereby cancer cells exhibit a high rate of glucose uptake and glycolysis, we speculated that USP13 might regulate the Warburg effect through PTEN. Indeed, knockdown of USP13 increased glucose uptake and glycolysis, which could be fully reversed by restoration of PTEN, as gauged by lactate production and glucose incorporation assays (Fig. 5g,h).

To investigate the biological function of USP13 in breast cancer cells in vivo, we subcutaneously implanted USP13-depleted SUM159 cells into nude mice and monitored tumour growth for more than nine days.
Figure 6 USP13 suppresses tumorigenesis and glycolysis in PTEN-positive but not PTEN-null breast cancer cells. (a) Growth curves of USP13- or USP13C345A-transduced MDA-MB-231 and BT549 cells. (b,c) Images (b) and quantification (c) of anchorage-independent growth of USP13- or USP13C345A-transduced MDA-MB-231 and BT549 cells. (d,e) Lactate secretion (d) and 2-deoxy-D-[14C]glucose (H3-DG) uptake (e) by USP13- or USP13C345A-transduced MDA-MB-231 and BT549 cells. (f) Tumour growth by 5 × 10^6 subcutaneously injected MDA-MB-231 cells transduced with USP13 or USP13C345A. (g,h) Tumour weight (g) and tumour images (h) of mice with subcutaneous injection of 5 × 10^6 MDA-MB-231 cells transduced with USP13 or USP13C345A, at day 50 after implantation. Data in a,e–g and i–k are mean ± s.e.m. n = 5 mice per group in f,g,j and k. Statistical significance was determined by a two-tailed, unpaired Student’s t-test. (m) Immunoblotting of USP13, PTEN, p-AKT, AKT and β-actin in tumour lysates from h and i. Data in a,c–e and i can be found in Supplementary Table 3. Uncropped images of blots are shown in Supplementary Fig. 6.

weeks. Mice bearing USP13 shRNA-expressing SUM159 cells showed increased tumour growth throughout the experiment compared with mice implanted with control shRNA-infected cells (Fig. 5i). At 65 days after tumour cell implantation, we observed a 2.5-fold increase in without knockdown of PTEN. (j) Tumour growth by 5 × 10^6 subcutaneously injected BT549 cells transduced with USP13 or USP13C345A (k,l) Tumour weight (k) and tumour images (l) of mice with subcutaneous injection of 5 × 10^6 BT549 cells transduced with USP13 or USP13C345A, at day 55 after implantation. Data in a,c–g and i–k are mean ± s.e.m. n = 5 mice per group in f,g,j and k. Statistical significance was determined by a two-tailed, unpaired Student’s t-test. (m) Immunoblotting of USP13, PTEN, p-AKT, AKT and β-actin in tumour lysates from h and i. Data in a,c–e and i can be found in Supplementary Table 3. Uncropped images of blots are shown in Supplementary Fig. 6.
confirmed that the effect of USP13 shRNA on PTEN and phospho-AKT was retained in these tumours (Fig. 5i). Therefore, loss of USP13 promotes tumorigenesis through downregulation of PTEN.

**The anti-tumour function of USP13 depends on PTEN status**

To further determine the dependence of the USP13 function on PTEN status, we compared the PTEN-positive cell line MDA-MB-231 and the PTEN-null cell line BT549 (Fig. 1c). Expression of USP13 (but not the C345A mutant) in MDA-MB-231 cells, which led to upregulation of PTEN and downregulation of phospho-AKT, phospho-FOXO1 and phospho-FOXO3 (Fig. 1c), significantly inhibited cell proliferation (Fig. 6a), colony formation on soft agar (Fig. 6b,c), lactate production (Fig. 6d), glucose uptake (Fig. 6e) and tumour growth (Fig. 6f–h), and knockdown of PTEN (Supplementary Fig. 2b) rescued the proliferation of USP13-overexpressing MDA-MB-231 cells (Fig. 6i). In stark contrast, none of these effects was observed in USP13-overexpressing BT549 cells (Fig. 6a–c,j–l), which showed no substantial difference in AKT phosphorylation compared with mock-infected cells (Fig. 1c). Western blot analysis of tumour lysates confirmed that the effect of USP13 on PTEN and phospho-AKT was retained in tumours formed by USP13-overexpressing MDA-MB-231 or BT549 cells (Fig. 6m). Taken together, USP13 has a PTEN-dependent tumour-suppressing function.

**USP13 is downregulated in human breast tumours and correlates with PTEN protein levels**

PTEN plays a pivotal role in human breast cancer suppression and is dose-dependent. Female patients with Cowden syndrome have partial loss of PTEN due to heterozygous germline PTEN mutations and are estimated to have a 25–50% risk of developing breast cancer29. Genetic analysis of mouse models has revealed Pten haploinsufficiency and dose dependence in breast tumour suppression30. Moreover, whereas approximately 5% of sporadic breast tumours harbour PTEN mutations9, loss of PTEN immunoreactivity is found in nearly 40% (ref. 30), which indicates that post-transcriptional and post-translational regulation of PTEN may contribute substantially to the development of human breast cancer. To determine the relevance of regulation of PTEN by USP13 in patients, we performed immunohistochemical staining of PTEN and USP13 (Fig. 7a) on the breast cancer progression tissue microarrays from the National Cancer Institute31, with antibodies validated for immunohistochemistry (Supplementary Fig. 5). Notably, downregulation of PTEN and USP13 was observed in 73.8% (152 of 206) and 41.3% (83 of 201) of breast tumours, whereas only 31.8% (14 of 44) and 13.2% (5 of 38) of normal mammary tissues exhibited low expression of PTEN and USP13 (Fig. 7b,c), respectively, suggesting that both PTEN and USP13 are downregulated in human breast tumours. Moreover, a significant positive correlation (R = 0.25, P = 4 × 10⁻⁴) between PTEN and USP13 protein levels was observed in these breast carcinomas, in which 88% (73 of 83) of the tumours with low USP13 expression also exhibited low PTEN expression (Fig. 7d). However, it should be noted that 38.8% (78 of 201) of total tumour specimens had low PTEN expression but high USP13 expression (Fig. 7d). Collectively, these data suggest that loss of USP13 may contribute to loss of PTEN in a substantial fraction of human tumours, whereas in other tumours PTEN can be inactivated by different mechanisms, including genetic alterations and upregulation of PTEN ubiquitin ligases (such as NEDD4-1 (ref. 14) and WW2 (ref. 15)).

**DISCUSSION**

The present study identified USP13 as a PTEN deubiquitylase and a tumour-suppressing protein. Besides USP13, another two PTEN-interacting DUBs, USP7 (HAUSP) and USP10, also exhibited a growth-inhibitory effect (Supplementary Fig. 1b–d), which might be explained by USP7-mediated delocalization of PTEN (ref. 18) and USP10-mediated stabilization of p53 (ref. 32), respectively. However, neither USP7 nor USP10 regulates PTEN protein levels (Supplementary
Fig. 1a and Supplementary Fig. 4a,b). In contrast, here we report USP13 as the first PTEN deubiquitylase that reverses the polyubiquitylation of PTEN, leading to PTEN stabilization and tumour suppression. Whereas most of the USP7 (HAUSP) protein is present in the nucleus\(^{18}\), it is consistent with its role in reversing the mono-ubiquitylation of nuclear PTEN and promoting PTEN export from the nucleus, USP13 is predominantly cytoplasmic or membrane-bound (Figs 2a,b and 7a and Supplementary Fig. 5), which is consistent with its role in reversing the polyubiquitylation of cytoplasmic or membrane-bound PTEN protein.

In contrast to the fast turnover of another major tumour suppressor protein, p53 (half-life: 5–20 min; ref. 33), PTEN has a relatively long half-life (3–6 h; Fig. 4a–d). We propose that unlike p53, PTEN is by default a relatively stable protein but its degradation is accelerated on upregulation of PTEN ubiquitin ligases or downregulation of PTEN deubiquitylases. As USP13 is downregulated in human breast tumours and correlates with PTEN expression, and because a large fraction of human cancers exhibit loss of only one PTEN allele\(^{34}\), we propose that loss of USP13 may drive breast tumorigenesis in mammatory tissues with heterozygous inactivation of PTEN. Future studies are needed to determine the physiological functions of USP13 and how USP13 expression is lost in human cancer.

METHODS

Methods and any associated references are available in the online version of the paper.

Note: Supplementary Information is available in the online version of the paper.

ACKNOWLEDGEMENTS

We thank J. Yuan, Z. Gong, A. Sorokin, J. Wang, N. Li, L. Feng and L. Li for reagents and technical assistance. This work is supported by US National Institutes of Health grants R00CA138572 (to L.M.) and R01CA166051 (to L.M.) and a Cancer Prevention and Research Institute of Texas Scholar Award R1004 (to L.M.).

AUTHOR CONTRIBUTIONS

J.Z. and L.M. conceived and designed the study and wrote the manuscript. J.Z. and L.M. provided the reagents and technical assistance. This work is supported by US National Institutes of Health grants R00CA138572 (to L.M.) and R01CA166051 (to L.M.) and a Cancer Prevention and Research Institute of Texas Scholar Award R1004 (to L.M.).

COMPETING FINANCIAL INTERESTS

The authors declare no competing financial interests.

Published online at www.nature.com/doifinder/10.1038/ncb2874
Reprints and permissions information is available online at www.nature.com/reprints

1. Leevers, S. J., Vanhaesebroeck, B. & Waterfield, M. D. Signalling through phosphoinositide 3-kinases: the lipids take centre stage. Curr. Opin. Cell Biol. 11, 219–225 (1999).
2. Maehama, T. & Dixon, J. E. The tumour suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem. 273, 13375–13378 (1998).
3. Di Cristofano, A., Pesce, B., Cordon-Cardo, C. & Pandolfi, P. P. PTEN is essential for embryonic development and tumour suppression. Nat. Genet. 19, 348–355 (1998).
4. Garcia-Cao, I. et al. Systemic elevation of PTEN induces a tumour-suppressive metabolic state. Cell 149, 49–62 (2012).
5. Song, M. S., Salmina, L. & Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 13, 283–296 (2012).
6. Liaw, D. et al. Germline mutations of the PTEN gene in Cowden disease, an inherited breast and thyroid cancer syndrome. Nat. Genet. 16, 64–67 (1997).
7. Li, J. et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275, 1943–1947 (1997).
8. Steck, P. A. et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15, 356–362 (1997).
9. Hollander, M. C., Blumenthal, G. M. & Dennis, P. A. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat. Rev. Cancer 11, 289–301 (2011).
10. Shi, Y., Paluch, B. E., Wang, X. & Jiang, X. PTEN at a glance. J. Cell Sci. 125, 4687–4692 (2012).
11. Wang, X. & Jiang, X. Post-translational regulation of PTEN. Oncogene 27, 5454–5463 (2008).
12. Fata, J. E., Debnath, S., Jenkins, E. C. Jr. & Fournier, M. V. Nongenomic mechanisms of PTEN regulation. Int. J. Cell Biol. 2012, 379685 (2012).
13. Trotman, L. C. et al. Ubiquitination regulates PTEN nuclear import and tumour suppression. Cell 128, 141–156 (2007).
14. Wang, X. et al. NEDD4-1 is a proto-oncogenic ubiquitin ligase for PTEN. Cell 128, 129–139 (2007).
15. Midda, S. et al. WWP2 is an E3 ubiquitin ligase for PTEN. Nat. Cell Biol. 13, 728–733 (2011).
16. Van Themsche, C., Leblanc, V., Parent, S. & Asselin, E. X-linked inhibitor of apoptosis protein (XIAP) regulates PTEN ubiquitination, content, and compartmentalization. J. Biol. Chem. 284, 20462–20466 (2009).
17. Ahmed, S. F. et al. The chaperone-assisted E3 ligase C terminus of Hsc70-interacting protein (CHIP) targets PTEN for proteosomal degradation. J. Biol. Chem. 287, 15996–16006 (2012).
18. Song, M. S. et al. The deubiquitylation and localization of PTEN are regulated by a HAUSP-PML network. Nature 455, 813–817 (2008).
19. Wilkinson, K. D. Regulation of ubiquitin-dependent processes by deubiquitinating enzymes. FASEB J. 11, 1245–1256 (1997).
20. Weigelt, B., Warne, P. H. & Downward, J. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs. Oncogene 30, 3222–3233 (2011).
21. Hollestelle, A., Elstrodt, F., Nagel, J. H., Kallemeijn, W. W. & Schutte, M. Phosphatidylinositol-3-OH kinase or RAS pathway mutations in human breast cancer cell lines. Mol. Cancer Res. 5, 195–201 (2007).
22. Zhao, X., Fiske, B., Kawakami, A., Li, J. & Fisher, D. E. Regulation of MITF stability by the USP13 deubiquitinase. Nat. Commun. 2, 414 (2011).
23. Song, M. S. et al. Nuclear PTEN regulates the APC-CDH1 tumour-suppressive complex in a phosphatase-independent manner. Cell 144, 187–199 (2011).
24. Lee, J. et al. Crystal structure of the PTEN tumour suppressor: implications for its phosphoinositide phosphatase activity and membrane association. Cell 99, 323–334 (1999).
25. Elstrom, R. L. et al. Akt stimulates aerobic glycolysis in cancer cells. Cancer Res. 64, 3892–3899 (2004).
26. Manning, B. D. & Cantley, L. C. AKT/PKB signalling: navigating downstream. Cell 129, 1261–1274 (2007).
27. Warburg, O. On the origin of cancer cells. Science 123, 309–314 (1956).
28. Gustafson, S., Zbuk, K. M., Scacheri, C. & Eng, C. Cowden syndrome. Semin. Oncol. 34, 428–434 (2007).
29. Alimonti, A. et al. Subtle variations in Pten dose determine cancer susceptibility. Nat. Genet. 42, 454–458 (2010).
30. Perez-Tenorio, G. et al. PIK3CA mutations and PTEN loss correlate with similar prognostic factors and are not mutually exclusive in breast cancer. Clin. Cancer Res. 13, 3577–3584 (2007).
31. Chen, D. et al. UPR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat. Med. 18, 1511–1517 (2012).
32. Yuan, J., Luo, K., Zhang, L., Cheville, J. C. & Lou, Z. USP10 regulates p53 localization and stability by deubiquitinating p53. Cell 140, 384–396 (2010).
33. Giaccia, A. J. & Kastan, M. B. The complexity of p53 modulation: emerging patterns from divergent signals. Genes. Dev. 12, 2973–2983 (1998).
34. Salmena, L., Carracedo, A. & Pandolfi, P. P. Tenets of PTEN tumour suppression. Cell 133, 403–414 (2008).
Methods

Cell culture. The HEK293T, HeLa, PC3, MCF10A, MCF7, MDA-MB-231 MDA-MB-436, MDA-MB-468, T47D and BT549 cell lines were from the American Type Culture Collection and were cultured under conditions specified by the manufacturer. The HCT116 cell line was kindly provided by U.S. Frazier (Medical University of South Carolina, USA) and cultured as described at http://www.asternard.com/Astemrd_human_tissues/159PT.htm. The HCT116 and H1T16 cell lines were described previously. For insulin stimulation, cells were starved in serum-free medium overnight, followed by treatment with 10 ng/ml insulin (Roche) for 15 min. The AKT inhibitor MK-2206 was purchased from Selleckchem and was used at 1 μM.

Plasmids and shRNA. Thirty DUB ORFs were purchased from the Dana-Farber/Harvard Cancer Center DNA Resource Core and individually subcloned into the pBabe-SBF vector using the Gateway system (Invitrogen). Five PTEN-encoding DUB ORFs were subcloned into a FLAG-tagged retroviral vector. GST-tagged USP13 was generated by subcloning into the pIRES vector (Invitrogen). Full-length PTEN ORF and various deletion mutant constructs were described previously. The following shRNA clones were from Open Biosystems by using TaqMan probes (Life Technologies): PTEN, Hs02621230_s1; USP8, Hs01064676_s1; USP13, Hs01063756_m1; and USP14, Hs00906034_m1. Quantitative PCR was performed on a CFX96 instrument (Bio-Rad) by using TaqMan probes (Life Technologies): PTEN, Hs02621230_s1; USP8, Hs01064676_s1; USP13, Hs01063756_m1; and USP14, Hs00906034_m1. The SUM159 cell line was from S. Ethier (Medical University of South Carolina, USA) and cultured as described previously.

Immunoprecipitation and pulldown assays. The complexes were washed twice with 1× Laemmli buffer and subjected to immunoblotting with the indicated antibodies.

Tandem affinity purification. HeLa cells were transfected with SBF-tagged PTEN or USP13. The expression of exogenous protein was confirmed by immunoblotting. For affinity purification, a total of twenty 10-cm dishes of HeLa cells expressing SBF-tagged PTEN or USP13 were lysed in NETN buffer containing protease inhibitors for 20 min at 4 °C. Crude lysates were cleared by centrifugation, and the supernatants were incubated with 300 μl streptavidin–Sepharose beads (Amersham) for 2 h at 4 °C. The beads were washed three times with NETN buffer, and the bound proteins were eluted by boiling in 1× Laemmli buffer and subjected to immunoblotting with the indicated antibodies.

Mass spectrometry. After Coomassie blue staining, excised gel pieces were subjected to in-gel trypsin digestion and dried. Samples were reconstituted in 5 μl of HPLC solvent A (2.5% acetonitrile and 0.1% formic acid). A nanoscale reverse-phase HPLC capillary column was created by packing 5 μm C18 spherical silica beads into a fused silica capillary (100 μm inner diameter; ~20 cm length) with a flame-drawn tip. After the column was equilibrated, each sample was loaded onto the column by a Famos autosampler (LC Packings). A gradient was formed and peptides were eluted with increasing concentrations of solvent B (97.5% acetonitrile and 0.1% formic acid). Eluted peptides were subjected to electrospray ionization and then entered an LTQ Velos ion-trap mass spectrometer (ThermoFisher). Peptides were detected, isolated and fragmented to produce a tandem mass spectrum of specific fragment ions for each peptide. Peptide sequences (and hence protein identity) were determined by matching protein databases with the acquired fragmentation pattern by using the software program SEQUEST (version 28, ThermoFisher). Mass tolerance was set to 2.0 for precursor ions and 1.0 for fragment ions. The database searched was the Human IPI database (version 3.6). The number of entries in the database was 160,900, which included both the target (forward) and the decoy (reverse) human sequences. Spectral matches were filtered to contain a less than 1% false discovery rate at the peptide level based on the target–decoy method. When peptides matched to multiple proteins, the peptide was assigned so that only the most logical protein was included. The same principle was used for isoforms when present in the database. The longest isoform was reported as the match.

Immunofluorescence. Cells were cultured in chamber slides overnight and fixed with 3.7% formaldehyde in PBS for 10 min at 4 °C, followed by permeabilization with 0.5% Triton X-100 in PBS for 10 minutes. Cells were then blocked for nonspecific binding with 10% goat serum in PBS and 0.1% Tween-20 (PBST) overnight, and incubated with the antibody against PTEN (1:100, Santa Cruz, SC-7974, Clone A2B1) or USP13 (1:300, Bethyl, A302-762A) for 1 h at room temperature, followed by incubation with Alexa Fluor 488 goat anti-mouse IgG (1:1000, Invitrogen, A11001) or Alexa Fluor 594 goat anti-rabbit IgG (1:1000, Invitrogen, A11012) for 30 min at room temperature. Coverslips were mounted on slides using anti-fade mounting medium with DAPI. Immunofluorescence images were acquired on a Zeiss Axio Observer Z1 fluorescence microscope. For each channel, all images were acquired with the same settings.

In vitro binding assay. Bacterially expressed GST–GFP or GST–USP13 was retained on glutathione–Sepharose beads (Amersham) and incubated with extracts of FLAG-PTEN-transfected 293T cells for 1 h at 4 °C. The complexes were washed three times with NETN buffer, eluted by boiling in SDS sample buffer and separated by SDS-PAGE. Immunoblotting was done with the antibody to FLAG.

Immunoprecipitation and pulldown assays. Cells were collected and lysed in NETN buffer containing protease inhibitors (Roche). For pulldown of SFB-tagged proteins, cell extracts were incubated with 5-μg beads for 2 h at 4 °C. Immunoprecipitation of protein complexes, cell extracts were pre-cleared with protein–A/G beads (Santa Cruz, SC-2003) and incubated with the indicated antibody for 2 h at 4 °C. The beads were washed three times with NETN buffer, and the bound proteins were eluted by boiling in 1× Laemmli buffer and subjected to immunoblotting with the indicated antibodies.

Cell proliferation assay. Equal numbers of cells were plated in 12-well plates in triplicate. From the next day, cells were fixed with 10% methanol and stained with 0.1% crystal violet (dissolved in 10% methanol) every day. After staining, wells were washed three times with PBS and stained with acetic acid. The absorbance of the crystal violet solution was measured at 590 nm.

RNA isolation and quantitative PCR. Total RNA was isolated with TRIzol reagent (Life Technologies) and then reverse transcribed with an iScript cDNA Synthesis Kit (Bio-Rad). Quantitative PCR was performed on a CFX36 instrument (Bio-Rad) using TaqMan probes (Life Technologies): PTEN, Hs00262130_m1; USP13, Hs00187594_m1; GAPDH, Hs00758991_g1. Data were normalized to GAPDH.
Anchorage-independent growth assay. Cells were resuspended in 1 ml of 0.35% low-melting agarose (Invitrogen) in DMEM supplemented with 10% FBS and plated in triplicate in six-well plates on 1 ml of pre-solidified 0.65% agarose in the same medium, with 1 ml of medium covering the cells. After incubation at 37 °C in 5% CO2 for 3–4 weeks, plates were stained with crystal violet and scanned on a GelDoc imager system (Oxford Optronix). Colonies were counted by using the ImageJ program (http://rsbweb.nih.gov/ij/download.html).

Deubiquitylation of PTEN in vivo and in vitro. For the in vivo deubiquitylation assay, HEK293T cells were transfected with MYC–PTEN, HA–ubiquitin and USP13 ORF or shRNA, and then treated with 10 μM MG132 (Fisher Scientific) for 6 h. MYC–PTEN was immunoprecipitated with MYC beads and subjected to immunoblotting with antibodies against HA and MYC. For preparation of PTEN as the substrate for the in vitro deubiquitylation assay, HEK293T cells were transfected with SFB–PTEN with or without HA–ubiquitin co-transfection and were treated with 10 μM MG132 for 6 h. Unubiquitylated or ubiquitylated SFB–PTEN was purified from the cell extracts with streptavidin–Sepharose 4B beads. After extensive washing with NETN buffer, the bound proteins were eluted with NETN buffer containing 2 mg ml−1 biotin. GST-tagged USP13 or the USP13C34A mutant was expressed in the Escherichia coli strain BL21. After induction with 0.4 mM IPTG, cells were lysed, and GST–USP13 was purified with glutathione–Sepharose 4B beads (Amersham Biosciences) and eluted with PBS containing 10 mM L-glutathione (Sigma). Alternatively, SFB-tagged USP13 or the USP13C34A mutant was transfected into HEK293T cells, purified with streptavidin–Sepharose beads and eluted with biotin. An in vitro deubiquitylation reaction was performed as described previously32 with minor modifications: briefly, eluted SFB–PTEN was incubated with purified USP13 in deubiquitylation buffer (50 mM Tris-HCl (pH 8.0), 50 mM NaCl, 1 mM EDTA, 10 mM dithiothreitol and 5% glycerol) for 2 h at 37 °C. After reaction, PTEN was immunoprecipitated with the antibody against PTEN or FLAG. The beads were washed with deubiquitylation buffer, and the bound proteins were eluted by boiling in 1× Laemmli buffer and subjected to immunoblotting with the antibodies against HA, FLAG and PTEN.

Fractionation. Fractionation of nuclear and cytoplasmic proteins was done by using the NE-PER Nuclear and Cytoplasmic Extraction Kit (Thermo) according to the manufacturer’s protocol. After fractionation, 30 μg of protein was used for western blot analysis of PTEN in the cytoplasm and nucleus. HSP90 and lamin B were used as markers of cytoplasm and the nucleus, respectively.

Lactate production assay. Cells were plated in 24-well plates and cultured overnight. The culture medium was removed from the cells and the lactate production was expressed as lactate concentration per 104 viable cells.

Glucose uptake assay. Cells (2 × 105) were seeded in 12-well plates. The next day, cells were washed twice with PBS and then incubated in 1 ml PBS containing 0.1 mM 2-deoxyglucose (Sigma) and 1 μCi ml−1 2-deoxy-D-[3H]glucose (Amersham). After incubation for 30 minutes, cells were washed three times with PBS and lysed. [3H]Glucose uptake was detected in 10 ml of scintillant on a Liquid Scintillation Analyser TRI-CARB 3100TR (Packard). Non-specific deoxyglucose uptake was measured in the presence of 20 μM cytochalasin B (Sigma) and was subtracted from the total uptake to obtain specific glucose uptake.

In vivo tumorigenesis study. All animal experiments were performed in accordance with a protocol approved by the Institutional Animal Care and Use Committee of MD Anderson Cancer Center. When used in a power calculation, our sample size predetermination experiments indicated that 5 mice per group can identify the expected effect of USP13 or PTEN on tumour size and weight (P < 0.05) with 100% power. Animals were randomly assigned to different groups. Tumour cells (5 × 106) in 30 μl growth medium (mixed with Matrigel at a 1:1 ratio) were injected subcutaneously into the flank of six- to eight-week-old female nude mice using a 100-μl Hamilton microlitre syringe. Tumour size was measured every five days using a caliper, and tumour volume was calculated using the standard formula: 0.5 × L × W2, where L is the longest diameter and W is the shortest diameter. Mice were euthanized when they met the institutional euthanasia criteria for tumour size and overall health condition. The tumours were removed, photographed and weighed. A laboratory technician (M Wang) who provided animal care and measured tumour growth was blinded to the group allocation during all animal experiments and outcome assessment.

Patient study. The breast cancer progression tissue microarrays were purchased from the National Cancer Institute Cancer Diagnosis Program. These tissue microarrays consist of different case sets, including 201–206 analyzable cases of breast carcinoma and 38–44 analyzable cases of normal breast tissue. Samples were deparaffinized and rehydrated. Antigen retrieval was done by using 0.01 M sodium-citrate buffer (pH 6.0) in a microwave oven. To block endogenous peroxidase activity, the sections were treated with 1% hydrogen peroxide in methanol for 30 min. After 1 h pre-incubation in 10% normal serum to prevent nonspecific staining, the samples were incubated with the antibodies against PTEN (1:50, Dako, M3627, Clone 6H2.1) and USP13 (1:1,500, Bethyl, A302-762A) at 4 °C overnight. The sections were then incubated with a biotinylated secondary antibody, followed by incubation with avidin–biotin peroxidase complex solution (1:100) for 1 h at room temperature. Colour was developed with the 3-aminobenzidine chromogen (ABC) solution. Counterstaining was carried out using Mayer’s haematoxylin. All immunostained slides were scanned on the Automated Cellular Image System III (ACIS III) for quantification by digital image analysis. A total score of protein expression was calculated from both the percentage of immunopositive cells and immunostaining intensity. High and low protein expression was defined using the mean score of all samples as a cutoff point. The χ2 test was used for statistical analysis of the correlation between PTEN and USP13, and the correlation of PTEN or USP13 with tissue type (normal versus cancer).

Statistical analysis. Each experiment was repeated three times or more. Unless otherwise noted, data are presented as mean ± s.e.m., and Student’s t-test (unpaired, two-tailed) was used to compare two groups for independent samples. The data analysed by t-test meet normal distribution; we used an f-test to compare variances, and the variances are not significantly different. Therefore, when using an unpaired t-test, we assumed equal variance, and no samples were excluded from the analysis. P < 0.05 was considered statistically significant.
Supplementary Figure 1 Effects of five PTEN-interacting deubiquitinases on cell proliferation and colony formation. (a) Five FLAG-tagged DUBs were expressed in MCF7 cells, immunoprecipitated with FLAG beads and immunoblotted with antibodies to PTEN and FLAG. (b) Growth curves of MCF7 cells transduced with USP7, USP8, USP10, USP13 or USP39. (c, d) Images (c) and quantification (d) of anchorage-independent growth of MCF7 cells transduced with USP7, USP8, USP10, USP13 or USP39. Data in (b) and (d) are the mean of 3 wells per group and error bars indicate s.e.m. The experiments were repeated 3 times. Statistical significance was determined by two-tailed, unpaired Student’s t test. Uncropped images of blots are shown in Supplementary Fig. S6.
**Supplementary Figure 2** Regulation of PTEN and AKT signaling by USP13. (a) Immunoblotting of USP13, PTEN and β-actin in a series of human breast cancer cell lines. (b) Immunoblotting of USP13, PTEN, p-AKT, AKT, p-FOXO1/3, FOXO1 and HSP90 in MDA-MB-231 cells transduced with USP13 alone or in combination with PTEN shRNA. (c) Immunoblotting of FLAG-USP13, HA-GFP and β-actin in 293T cells transfected with USP13 shRNA in combination with FLAG-tagged wild-type USP13 or an RNAi-resistant mutant of USP13 (USP13-RE). Co-transfected HA-GFP serves as the control for transfection. (d) Immunoblotting of USP13, PTEN, p-AKT, AKT, p-FOXO1/3, FOXO1 and HSP90 in USP13 shRNA-transduced SUM159 cells with or without ectopic expression of an RNAi-resistant mutant of USP13 (USP13-RE). (e) Immunoblotting of USP13, PTEN, p-AKT, AKT and β-actin in USP13 shRNA-transduced SUM159 cells with or without ectopic expression of PTEN. Cells were serum-starved and treated with 10 ng/ml insulin for 15 minutes. Uncropped images of blots are shown in Supplementary Fig. S6.
Supplementary Figure 3 USP13 does not alter PTEN mRNA levels. (a) qPCR of PTEN and USP13 in USP13 shRNA-transduced SUM159 cells. (b) qPCR of PTEN in MDA-MB-231 cells transduced with wild-type USP13 or the USP13<sup>C345A</sup> mutant. Data in (a) and (b) are the mean of 3 triplicates per group and error bars indicate s.e.m. The experiments were repeated 3 times.
Supplementary Figure 4 USP7, USP10, USP8 and USP39 do not regulate PTEN protein levels. Immunoblotting of the USP, PTEN and HSP90 in SUM159 cells with knockdown of USP7 (a), USP10 (b), USP8 (c) or USP39 (d). Uncropped images of blots are shown in Supplementary Fig. S6.
Supplementary Figure 5 Validation of the PTEN- and USP13-specific antibodies for immunohistochemistry. The PTEN antibody was validated using BT549 (PTEN-null) and MCF7 (PTEN-positive) cell lines. The USP13 antibody was validated using parental SUM159 cells (USP13-positive) and USP13 shRNA-transduced SUM159 cells (USP13-depleted). To prepare sections, we fixed the cell pellet in formalin and embedded it in paraffin. Brown staining indicates positive immunoreactivity. Scale bar: 50 μm.
Supplementary Figure 6 Uncropped images of immunoblots.
Supplementary Figure 6 continued
Supplementary Figure 6 continued
Supplementary Table Legends

Supplementary Table 1 List of PTEN-interacting proteins identified by TAP-MS analysis.
Supplementary Table 2 List of USP13-interacting proteins identified by TAP-MS analysis.
Supplementary Table 3 Source data.